Ironwood医药宣布了一项重要的人事任命与临床试验进展。Jeffrey Silber博士被正式任命为公司首席医疗官,并同时兼任研究与药物开发部门的负责人。这一任命旨在加强公司研发管线与临床开发战略的领导力。
与此同时,公司备受关注的STARS-2临床试验已于今年六月正式启动。该试验目前正处于患者招募的活跃阶段,标志着相关研究项目进入了关键的临床实施环节。
Ironwood医药宣布了一项重要的人事任命与临床试验进展。Jeffrey Silber博士被正式任命为公司首席医疗官,并同时兼任研究与药物开发部门的负责人。这一任命旨在加强公司研发管线与临床开发战略的领导力。
与此同时,公司备受关注的STARS-2临床试验已于今年六月正式启动。该试验目前正处于患者招募的活跃阶段,标志着相关研究项目进入了关键的临床实施环节。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.